Drug

Sino Biopharmaceutical's CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B
Breakthrough therapyChia Tai Tianqing Pharmaceutical

Sino Biopharmaceutical’s CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Sino Biopharmaceutical Limited (HKG: 1177) announced that TQ‑A3334 (a Toll-like receptor 7 agonist) and TQA3605 (a core protein allosteric modulator, CpAM), both Category 1 innovative drugs independently developed by its…

FDA Expands Pfizer's TALZENNA-XTANDI Approval to Earlier-Line HRR-Mutated Metastatic Prostate Cancer

FDA Expands Pfizer’s TALZENNA-XTANDI Approval to Earlier-Line HRR-Mutated Metastatic Prostate Cancer

Hengrui Wins NMPA Trial Clearance for First-in-Class SHR-2005 Combination in Bladder Cancer

Hengrui Wins NMPA Trial Clearance for First-in-Class SHR-2005 Combination in Bladder Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
BrightGene Bio-Medical TechnologyFirst-mover generic

BrightGene’s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China’s First Domestic COPD Treatment Alternative

Clinical trial approval / initiationHKG: 3696

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson’s Disease with Global Clinical Trials Underway

ADC / XDCClinical trial approval / initiation

Henlius HLX43 PD-L1 ADC Gains NMPA Approval for Advanced Solid Tumor Trials with Bevacizumab

Roche's Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion
OphthalmologyOTCMKTS: RHHBY

Roche’s Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion

Show More